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1  | INTRODUC TION
A new viral pneumonia was first detected in Wuhan, China, and 
was found to be caused by a novel coronavirus, later identified as 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
that has since then caused a pandemic. Previous reports have 
shown that certain laboratory parameters correlated with disease 
severity and mortality in SARS-CoV-2 infection.1 The levels of 
D-dimer, an important prognostic factor, were found to be higher 
in patients with a clinically severe case of SARS-CoV-2 than in 
nonsevere cases.2 A better understanding of this prognostic 
factor can help physicians predict the disease severity and need 
for intensive care unit (ICU) care in patients infected with SARS-
CoV-2. This meta-analysis aimed to determine the relationship 
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Introduction: The novel severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has caused a pandemic. Many studies have shown that several laboratory 
parameters are related to disease severity and mortality in SARS-CoV-2 cases. This 
meta-analysis aimed to determine the relationship of a prognostic factor, D-dimer, 
with disease severity, need for intensive care unit (ICU) care, and mortality in SARS-
CoV-2 patients.
Methods: A systematic search for all observational studies and trials involving adult 
patients with SARS-CoV-2 that had any data related to D-dimer on admission was 
conducted using PubMed, Science Direct, Scopus, ProQuest, and MedRxiv data-
bases. We performed random-effects inverse-variance weighting analysis using 
mean difference (MD) of D-dimer values for outcomes such as disease severity, mor-
tality, and need for ICU care.
Results: A total of 29 studies (4,328 patients) were included in this meta-analysis, 
which revealed a higher mean of D-dimer levels on admission in severe patients than 
in nonsevere patients (MD = 0.95, [95% confidence interval (CI): 0.61-1.28], P < .05; 
I2 = 90%). The nonsurvivor group had a higher pooled MD of D-dimer values on ad-
mission (MD = 5.54 [95% CI: 3.40-7.67], P < .05; I2 = 90%). Patients who needed ICU 
admission had insignificantly higher D-dimer values than patients who did not need 
ICU admission (MD = 0.29, [95% CI: −0.05 to 0.63], P = .10; I2 = 71%).
Conclusion: Elevated D-dimer levels on admission were associated with an increased 
risk of disease severity and mortality in patients with SARS-CoV-2 infection.
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of D-dimer with disease severity and mortality in SARS-CoV-2 
patients.
2  | METHODS
We conducted this study following the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We 
selected all observational studies and trials involving adult patients 
with SARS-CoV-2 that had any data on D-dimer values for compar-
ing different groups: severe vs. nonsevere; ICU vs. non-ICU; survivor 
vs. nonsurvivor. We excluded any study that did not have the re-
quired data, collect D-dimer data on admission, and report D-dimer 
data in numerical values.
A systematic literature search was carried out after receiving ap-
proval from the Institutional Review Board. Five different databases 
(PubMed, Science Direct, Scopus, ProQuest, and MedRxiv) were 
used to perform a systematic search of all the literature using the 
keywords “intensive” and “laboratory” and “COVID-19” or “coronavi-
rus 2019” or “2019-nCoV” or “SARS-CoV-2,” in the title, abstract, and 
medical subject heading (MeSH). We used “laboratory” as a search 
term instead of D-dimer because earlier studies did not consider 
D-dimer as an important factor, and hence, this factor was reported 
as data related to the laboratory report on admission. D-dimer levels 
were neither mentioned nor discussed separately in these reports. 
The reference lists of the studies included were screened to identify 
additional studies relevant to D-dimer.
Three investigators independently screened and assessed titles 
and abstracts before full-text retrieval. The other two authors re-
viewed the papers for final inclusion and extracted data including 
authors, year of publication, location, study design, peer-reviewed 
publication status, disease severity measurement, and D-dimer lev-
els in each comparison group.
The primary outcome in our meta-analysis was the D-dimer 
levels on admission based on the severity of the case. We used all 
definition of severity. If the study categorized disease severity into 
three or four groups, we combined all the data found in the mild 
and moderate group into one group as nonsevere; severe and criti-
cal groups were combined into one group as severe. The average of 
their mean and standard deviation was calculated using the formula 
in Table 7.7.a of the Cochrane Handbook.3 The secondary outcomes 
were D-dimer levels on admission based on mortality and intensive 
care need.
Two authors independently assessed the methodological qual-
ity assessment using the National Heart Lung and Blood Institute 
Quality Assessment Tool for Observational Cohort and Cross-
Sectional Studies. We conducted the meta-analysis using the mean 
difference (MD) for D-dimer levels. Mean and standard deviation 
values were extrapolated from the sample size, median, and in-
terquartile range (IQR), according to Wan et al4 We employed a 
fixed-effects and inverse-variance weighting using Review Manager 
(RevMan v5.3 2014). We carried out a subgroup analysis based on 
study design. We performed a sensitivity analysis based on peer 
review and age difference status. We evaluated inter- and intrastudy 
heterogeneity using the I2 statistic. We applied a random-effects 
meta-analysis if the heterogeneity is significant.
3  | RESULT
We identified a total of 111 records from the PubMed database, 
488 records from the ScienceDirect database, 20 records from 
the ProQuest database, 42 records from the Scopus database, 846 
records from the MedRxiv database, and 127 records from other 
sources as shown in Figure 1. One-hundred and fifty-one other stud-
ies were excluded because of incorrect population (4 studies), irrel-
evant exposure (83 studies), irrelevant outcome (42 studies), study 
not reported in English (1 study), D-dimer values not collected on 
admission (9 studies), and irrelevant severity criteria (12 studies). We 
excluded the study of Levy et al from our analysis because D-dimer 
measurements were missing in 78% of the patients and there was 
no information regarding the proportion of those missing in each 
group.5 Twenty-nine studies (4,328 patients) were included in the 
analysis.6-34
The baseline characteristics of the included studies are presented 
in Supplementary file 1. Twenty-six studies were retrospective, and 
three studies were prospective observational. Fifteen studies have 
already undergone peer review.6,12,14,16,18-21,24,25,27,30,31,33,34 One 
study provided a comparison between groups for disease severity 
and mortality.11 Most of the studies classified the disease sever-
ity according to the National Health Commission of the People's 
Republic of China. Only three studies considered subjects of similar 
age in both groups.28,30,33
Among the 29 studies included in this meta-analysis, most did 
not identify whether D-dimer values were reported as D-dimer units 
(DDU) or fibrinogen equivalent units (FEU). Only 3 studies clearly 
stated using FEU.20,22,30 Nine studies did not report the normal cut-
off value of D-dimer (Supplementary file 1).
We assessed all studies wherein all outcomes were obtained 
using a good and fair methodology (Supplementary file 1). None of 
the studies that were considered had any flaws in the analyses. The 
analyses were rigorous, and the conclusions drawn by the studies 
were credible. However, most studies did not assess exposure prior 
to outcome measurement and may have lacked sufficient timeframe 
for the outcomes to occur because of their cross-sectional design.
Random-effects meta-analysis revealed a higher mean of 
D-dimer levels on admission in severe patients than in nonsevere 
patients as shown in Table 1 (14 studies, MD = 0.95, [95% CI: 0.61-
1.28], P < .05; I2 = 90%). Subgroup analysis based on the study de-
sign showed a similar result in both subgroups. Sensitivity analysis 
based on the peer-reviewed status from 6 studies showed an MD 
of 0.68 with 95% CI 0.26-1.10 and I2 = 86% (Supplementary file 2).
Nonsurvivor group had a pooled higher mean difference 
of D-dimer values on admission as shown in Table 1 (9 studies, 
MD = 5.54 [95% CI: 3.40-7.67], P < .05; I2 = 90%) than survi-
vor groups. Sensitivity analysis showed similar result (5 studies, 
     |  3NUGROHO et al.
MD = 5.78, [95% CI: 2.94-8.63], P < .05; I2 = 84%) when we excluded 
nonpeer-reviewed studies. We did not perform a subgroup analysis 
based on study design because all included studies were retrospec-
tive observational.
Patients with need for ICU care had higher D-dimer values on 
admission than patients who did not need ICU care (seven studies, 
MD = 0.29, [95% CI: −0.05 to 0.63], P = .10; I2 = 71%) as shown 
in Table 1. Sensitivity analysis showed a similar result when we ex-
cluded studies that had significant age differences pertaining to par-
ticipants estimates (3 studies, MD = 4.35, [95% CI: −2.31 to 11.01], 
P = .20; I2 = 81%). However, the effect estimates changed and were 
found to be significant without improvement in heterogeneity (4 
studies, MD = 0.48, [95% CI: 0.21-0.76], P < .05; I2 = 66%) when we 
excluded nonpeer-reviewed studies.
4  | DISCUSSION
This meta-analysis showed that increasing D-dimer levels on ad-
mission were significantly associated with increased disease sever-
ity and mortality. The results obtained were similar to the results 
reported previously in two other systematic reviews.35,36 Pooled 
F I G U R E  1   Study flow chart (as per PRISMA guideline) [Colour figure can be viewed at wileyonlinelibrary.com]
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analysis by Shah et al demonstrated that patients who had D-dimer 
levels more than 0.5 mg/L had a twofold higher risk of developing 
a severe case of the disease and fourfold higher risk of mortality 
than those who had D-dimer levels less than 0.5 mg/L.36 Higher cut-
off value of D-dimer (>2 mg/L) was considered to be even better in 
predicting in-hospital mortality in SARS-CoV-2 with a sensitivity of 
92.3% and a specificity of 83.3% after adjusting for age, gender, and 
comorbidities.37
Our study also showed that patients with a need for ICU care 
had nonsignificant higher D-dimer values on admission than patients 
who did not need ICU care. An earlier study demonstrated that 
there was an increased incidence of thrombotic complications in pa-
tients treated in the ICU.38 Hypercoagulability state was also found 
in patients admitted to ICU where D-dimer levels were drastically 
increased.39 At the late stages of SARS-CoV-2, levels of fibrin-re-
lated markers (D-dimer and fibrin degradation product) were either 
moderately or markedly elevated in all cases of death suggesting a 
common coagulation activation and secondary hyperfibrinolysis 
condition in these patients.24
Histopathology studies on the lung biopsy of critical patients 
with SARS-CoV-2 revealed the presence of occlusion and micro-
thrombosis formation in pulmonary small vessels.40 The exact mech-
anism responsible for coagulopathy in SARS-CoV-2 patients is not 
yet identified. Whether SARS-CoV-2 can directly attack vascular 
endothelial cells expressing high levels of angiotensin-converting 
enzyme 2 (ACE2) leading to abnormal coagulation and sepsis is an 
aspect that still needs to be explored.
Our meta-analysis suggests that elevated D-dimer levels can 
be a marker of poor prognosis in patients with coronavirus dis-
ease (COVID-19). During a pandemic, risk stratification in triage is 
necessary, and D-dimer can be one of the potential indicators in the 
case of high-risk patients. However, only the presence of elevated 
D-dimer only is not a reason enough to start the administration of 
therapeutic anticoagulants.
To the best of our knowledge, this meta-analysis conducted using 
29 different studies is the largest that evaluates the prognostic role 
of D-dimer on admission in SARS-CoV-2 patients. However, several 
limitations should be noted in our study. First, there was substan-
tial heterogeneity across studies. Most of the studies included were 
retrospective with relatively small sample size. Second, the variation 
in reporting the unit of D-dimer inevitably might affect our interpre-
tation and analysis of the D-dimer data. Third, the analysis in this 
study was performed during the pandemic; researchers conducting 
studies in many areas affected by SARS-CoV-2 have not published 
their data as yet. Most of the studies included were from mainland 
China, while the remaining three studies were from the USA. Ethnic 
and geographical differences could distort the results of the analysis.
5  | CONCLUSIONS
Our meta-analysis demonstrated that elevated D-dimer levels on 
admission were associated with an increased risk of disease severity 
and mortality in SARS-CoV-2 infection.
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Severity 14 2190 0.95 [0.61, 
1.28]
<.05 90%
Retrospective 11 1557 1.30 [0.78, 
1.82]
<.05 91%
Prospective 3 633 0.54 [0.05, 
1.04]
<.05 90%
Sensitivity analysis 6 775 0.29 [−0.05, 
0.63]
<.05 86%
Mortality 9 1808 5.54 [3.40, 
7.67]
<.05 90%
Sensitivity analysisa  5 851 5.78 [2.94, 
8.63]
<.05 84%
Needs of ICU 7 657 0.29 [−0.05, 
0.63]
.1 71%
Sensitivity analysisa  4 241 0.48 [0.21, 
0.76]
<.05 66%
Sensitivity analysisb  3 89 4.35 [−2.31, 
11.01]
.2 81%
aSensitivity analysis based on peer-reviewed status. 
bSensitivity analysis based on age difference status. 
TA B L E  1   Summary of findings
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